Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GS 9350

Known as: 9350, GS, GS-9350, GS9350 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
PURPOSE This article reviews the clinical pharmacology, pharmacodynamic and pharmacokinetic (PK) properties, clinical efficacy… Expand
2014
2014
The HIV protease inhibitor (PI) ritonavir (RTV) has been widely used as a pharmacoenhancer for other PIs, which are substrates of… Expand
  • figure 1
  • table 1
  • table 1
  • table 2
2012
2012
There are 26 approved antiretroviral drugs available in 2012 in 6 mechanistic classes: reverse transcripatase inhibitors (both… Expand
Highly Cited
2011
Highly Cited
2011
Objective:To assess the safety and efficacy of two, single-tablet regimens for the initial treatment of HIV infection. Design… Expand
Review
2011
Review
2011
Elvitegravir is a potent, boosted, once-daily, HIV integrase inhibitor with antiviral activity against wild-type and drug… Expand
Highly Cited
2010
Highly Cited
2010
GS‐9350 is a new chemical entity under development as a potent, mechanism‐based inhibitor of human cytochrome P450 3A (CYP3A… Expand
Highly Cited
2010
Highly Cited
2010
Cobicistat (3, GS-9350) is a newly discovered, potent, and selective inhibitor of human cytochrome P450 3A (CYP3A) enzymes. In… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Highly Cited
2010
Highly Cited
2010
Objective: This study evaluated the relative bioavailability and pharmacokinetics of elvitegravir (EVG), emtricitabine (FTC… Expand
2009
2009
766 www.thelancet.com Vol 374 September 5, 2009 5 Steigbigel RT, Cooper DA, Kumar PN, et al, for the BENCHMRK Study Teams… Expand
2009
2009
  • AIDS patient care and STDs
  • 2009
  • Corpus ID: 36341942